BRAF and melanoma: The phase III trials BRIM-3 and BREAK-3 compared BRAF inhibitors to dacarbazine in patients with previously untreated stage IV or unresectable stage III BRAF V600E-positive melanoma, showing a BRAF inhibitor improves response rates, PFS, and OS compared with chemotherapy alone [103,104].